Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: The role of metformin

Minerva Endocrinologica

Volumn 37, Issue 1, 2012, Pages 25-40

  Weickert, M O ^a,b   Hodges, P ^a   Tan, B K ^b,c   Randeva, H S ^a,b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Adipokines; Insulin resistance; Metformin; Polycystic ovary syndrome

Indexed keywords

ADENYLATE KINASE; ADIPOCYTOKINE; ANDROGEN; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CLOMIFENE; CYCLIC AMP; FETUIN A; FOLLITROPIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 4; GONADORELIN; HYDROXYPROGESTERONE; INSULIN; INSULIN RECEPTOR; LEPTIN; LUTEINIZING HORMONE; METFORMIN; MUELLERIAN INHIBITING FACTOR; PEPTIDE YY; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; UNINDEXED DRUG; VASPIN;

ADIPOSE TISSUE; ANDROGEN BLOOD LEVEL; BLOOD PRESSURE; BLOOD VESSEL; BODY MASS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EMBRYO DEVELOPMENT; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; FERTILITY; FOOD AND DRUG ADMINISTRATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER; LIVER CELL; MENSTRUAL CYCLE; METABOLIC SYNDROME X; NEUROENDOCRINE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OOCYTE MATURATION; OVARY; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOGENESIS; PREGNANCY RATE; PREVALENCE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; REVIEW; SKELETAL MUSCLE; STEROIDOGENESIS;

ADIPOKINES; ANDROGENS; ENDOCRINE SYSTEM; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; HORMONES; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; MODELS, BIOLOGICAL; NEUROSECRETORY SYSTEMS; OBESITY; ORGAN SPECIFICITY; OVULATION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84860299848     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. Bjog 2006;113:1210-7. (Pubitemid 44401217)
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
3. Bergh C, Carlsson B, Olsson JH, Selleskog UHillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993;59:323-31. (Pubitemid 23057784)
4. Diamanti-Kandarakis E, Economou F, Palimeri SChristakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 2010;1205:192-8.
5. Lord JM, Flight IHNorman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Bmj 2003;327:951-3.
6. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 2006;49:1732-41. (Pubitemid 44025026)
7. Billa E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol 2009;25:427-34.
8. Isik S, Nursun Ozcan H, Ozuguz U, Berker D, Tutuncu Y, Akbaba G et al. Impaired Gallbladder Motility and the Effect of Metformin Therapy in Patients with Polycystic Ovary Syndrome. Clin Endocrinol (Oxf) 2011 [Epub ahead of print].
9. Gambineri A, Pelusi C, Vicennati V, Pagotto UPasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-96. (Pubitemid 34756169)
10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9. (Pubitemid 29036695)
11. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454-60. (Pubitemid 40615820)
12. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-54. (Pubitemid 38140845)
13. el-Roeiy A, Chen X, Roberts VJ, Shimasakai S, Ling N, LeRoith D et al. Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab 1994;78:1488-96.
14. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schofl C, Mohlig M et al. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 2009;94:5093-101.
15. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528-33. (Pubitemid 36623365)
16. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46. (Pubitemid 32268804)
17. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-9. (Pubitemid 34615238)
18. Sharma ST, Wickham EP, 3rdNestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 2007;13:373-9.
19. Costello M, Shrestha B, Eden J, Sjoblom PJohnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007,CD005552.
20. Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 2000;49:896-903. (Pubitemid 30349410)
21. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway lia a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69.
22. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 2006;55:819-25.
23. Komori T, Hotta N, Kobayashi M, Sakakibara F, Koh N, Sakamoto N. Biguanides may produce hypoglycemic action in isolated rat hepatocytes through their effects on L-alanine transport. Diabetes Res Clin Pract 1993;22:11-7.
24. Kumar N, Dey CS. Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells. Br J Pharmacol 2002;137:329-36.
25. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-35. (Pubitemid 40586223)
26. Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 2009;58:714-21.
27. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med 2002;13:73-88, vi.
28. Benitez R, Sir-Petermann T, Palomino A, Angel B, Maliqueo M, Perez F et al. [Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome]. Rev Med Chil 2001;129:707-12.
29. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-9. (Pubitemid 40529957)
30. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007;5:496-501. (Pubitemid 46575354)
31. Ciotta L, Pagano I, Stracquadanio M, Formuso C. Polycystic ovarian syndrome incidence in young women with non-alcoholic epatic steatosis. Minerva Ginecol 2011;63:429-37.
32. Ahima RS. Insulin resistance: cause or consequence of nonalcoholic steatohepatitis? Gastroenterology 2007;132:444-6. (Pubitemid 46108764)
33. Adams LAAngulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33.
34. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90. (Pubitemid 40769045)
35. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev CD003053.
36. Sabatini ME, Guo L, Lynch MP, Doyle JO, Lee H, Rueda BR et al. Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation. J Ovarian Res 2011;4:8.
37. Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 2009;25:1005-13.
38. Tosca L, Solnais P, Ferre P, Foufelle F, Dupont J. Metformin-induced stimulation of adenosine 5′ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod 2006;75:342-51. (Pubitemid 44268068)
39. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007;22:2967-73. (Pubitemid 351696807)
40. La Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 1999;72:985-9.
41. Zhang G, Garmey JC, Veldhuis JD. Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells. Endocrinology 2000;141:2735-42. (Pubitemid 32250433)
42. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-9. (Pubitemid 27525516)
43. Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase. J Biol Chem 2001;276:16767-71.
44. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505-9. (Pubitemid 32175664)
45. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000;105:199-205. (Pubitemid 30054359)
46. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 2003;88:1323-32. (Pubitemid 36337797)
47. Rice S, Pellatt LJ, Bryan SJ, Whitehead SA, Mason HD. Action of metformin on the insulin-signaling pathway and on glucose transport in human granulosa cells. J Clin Endocrinol Metab 2011;96:E427-35.
48. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188-91. (Pubitemid 24076735)
49. Genazzani AD, Strucchi C, Luisi M, Casarosa E, Lanzoni C, Baraldi E et al. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:36-43. (Pubitemid 43355096)
50. Roland AV, Moenter SM. Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood. Endocrinology 2011;152:618-28.
51. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002;87:5625-9. (Pubitemid 36034369)
52. Doogue MP, Begg EJ, Moore MP, Lunt H, Pemberton CJ, Zhang M. Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol 2009;68:875-82.
53. Schofl C, Horn R, Schill T, Schlosser HW, Muller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4607-10. (Pubitemid 35247048)
54. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006;155:337-45. (Pubitemid 44269452)
55. Weickert MO, Loeffelholz CV, Arafat AM, Schofl C, Otto B, Spranger J et al. Euglycemic hyperinsulinemia differentially modulates circulating total and acylatedghrelin in humans. J Endocrinol Invest 2008;31:119-24. (Pubitemid 351596971)
56. Weickert MO, Mohlig M, Spranger J, Schofl C, Loeffelholz CV, Riepl RL et al. Effects of euglycemic hyperinsulinemia and lipid infusion on circulating cholecystokinin. J Clin Endocrinol Metab 2008;93:2328-33. (Pubitemid 351831555)
57. Ren T, He J, Jiang H, Zu L, Pu S, Guo X et al. Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol. J Mol Endocrinol 2006;37:175-83. (Pubitemid 44288615)
58. Isik S. Impaired gallbladder motility in women with PCOS - role of free fatty acids with circulating cholecystokinin and other possible mechanism. Clin Endocrinol (Oxf) 2011 [Epub ahead of print].
59. Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism 2009;58:586-93.
60. Tsilchorozidou T, Batterham RL, Conway GS. Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). Clin Endocrinol (Oxf) 2008;69:936-42.
61. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. Faseb J 2008;22:1672-83. (Pubitemid 351811445)
62. Rabe K, Lehrke M, Parhofer KGBroedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-51.
63. Brzechffa PR, Jakimiuk AJ, Agarwal SK, Weitsman SR, Buyalos RP, Magoffin DA. Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:4166-9. (Pubitemid 26380435)
64. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen S, Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod 2000;6:873-6.
65. Hahn S, Haselhorst U, Quadbeck B, Tan S, Kimmig R, Mann K et al. Decreased soluble leptin receptor levels in women with polycystic ovary syndrome. Eur J Endocrinol 2006;154:287-94.
66. Iuorno MJ, Islam LZ, Veldhuis PP, Boyd DG, Farhy LS, Johnson ML et al. Leptin secretory burst mass correlates with body mass index and insulin in normal women but not in women with polycystic ovary syndrome. Metabolism 2007;56:1561-5. (Pubitemid 47562507)
67. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005;54:2712-9. (Pubitemid 41233594)
68. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009;15:297-307.
69. Trolle B, Lauszus FF, Frystyk JFlyvbjerg A. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertil Steril 2011;94:2234-8.
70. Huypens P, Quartier E, Pipeleers D, Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 2005;518:90-5. (Pubitemid 41133630)
71. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501-7.
72. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-61. (Pubitemid 43847911)
73. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008;57:801-8.
74. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006;3:e287.
75. Tan BK, Adya R, Shan X, Aghilla M, Lehnert H, Keay SD et al. The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. Atherosclerosis 2011;216:402-8.
76. Tomova A, Deepinder F, Robeva R, Kirilov G, Mechandjiev Z, Kumanov P. Anti-Mullerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res 2011;43:723-7.
77. Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G et al. The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol 2011;27:587-92.
78. Savastano S, Orio F Jr, Palomba S, Cascella T, Manguso F, Lupoli GA et al. Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;67:557-62. (Pubitemid 47416314)
79. Tan BK, Chen J, Adya R, Randeva HS. Phosphoprotein enriched in diabetes gene product (Ped/pea-15) is increased in omental adipose tissue of women with the polycystic ovary syndrome: ex vivo regulation of ped/pea-15 by glucose, insulin and metformin. Diabetes Obes Metab 2011;13:181-4.
80. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280:34661-6. (Pubitemid 41504597)
81. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009;58:2731:40.
82. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58:1971-7.
83. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007;88:401-5. (Pubitemid 47212138)
84. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006;91:5022-8. (Pubitemid 44917345)
85. Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:536-42.
86. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Loberg EM, Haaland T et al. Fetuin A in non-alcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 2011 [Epub ahead of print].
87. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res 2008;36:625-9.
88. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102:10610-5. (Pubitemid 41061602)
89. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-7.
90. von Loeffelholz C, Mohlig M, Arafat AM, Isken F, Spranger J, Mai K et al. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 2010;162:507-13.
91. Fujita H, Fujishima H, Morii T, Koshimura J, Narita T, Kakei M et al. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun 2002;298:345-9. (Pubitemid 35333711)
92. Ort T, Arjona AA, MacDougall JR, Nelson PJ, Rothenberg ME, Wu F et al. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose expiants, and normal mice. Endocrinology 2005;146:2200-9. (Pubitemid 40577507)
93. Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL et al. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004;19:48-53.
94. Gorar S, Culha C, Uc ZA, Dellal FD, Serter R, Aral S et al. Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol 2011;26:819-26.
95. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009;58:1532-8.
96. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-8.
97. Mai K, Bobbert T, Reinecke F, Andres J, Maser-Gluth C, Wudy SA et al. Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: a randomized, controlled trial. J Clin Endocrinol Metab 2008;93:3900-6.
98. Mai K, Bobbert T, Kullmann V, Andres J, Rochlitz H, Osterhoff M et al. Free fatty acids increase androgen precursors in vivo. J Clin Endocrinol Metab 2006;91:1501-7.
99. Ashokkumar N, Pari LRao Ch A. Effect of N-benzoyl-D-phenylalanine and metformin on insulin receptors in neonatal streptozotocin-induced diabetic rats: studies on insulin binding to erythrocytes. Arch Physiol Biochem 2006;112:174-81. (Pubitemid 44871045)
100. Richardson MC, Ingamells S, Simonis CD, Cameron IT, Sreekumar R, Vijendren A et al. Stimulation of lactate production in human granulosa cells by metformin and potential involvement of adenosine 5′ monophosphate- activated protein kinase. J Clin Endocrinol Metab 2009;94:670-7.